Our Austin

Austin Biotech Tiny Health Raised $33 Million

The funding will expand clinical research and the local company's B2B platform following a record-setting Series B.

Updated on Sept. 29, 2026 in Biotech

Isometric editorial illustration of a glass test tube on a clean laboratory surface, representing biotechnology research.
Austin-based biotech firm Tiny Health raised $33 million in a Series B round to scale its microbiome testing and B2B research platform. AI Illustration. Upload story photo >

Live Poll

Is now a good time to invest in personalized microbiome or health testing for your household?

Austin-based Tiny Health has secured $33 million in a Series B funding round, bringing the total capital raised by the biotech company to $46 million. This investment will support a new $5 million microbiome research initiative and scale the company's B2B services for healthcare practitioners.

Why it matters

As chronic conditions affect a significant portion of the U.S. population, Tiny Health aims to make microbiome testing more accessible through its AI-driven bioinformatics platform. The new capital provides the runway to accelerate clinical research and educational outreach for providers.

Tiny Health secured $33 million in Series B funding, pushing total investment to $46 million. The company currently supports more than 6,000 healthcare practitioners using a proprietary dataset of 200,000 profiles.

The players

Tiny Health

An Austin-based biotech company specializing in gut and vaginal microbiome testing.

B Capital

The investment firm that led the latest funding round for the company.

The details

Led by B Capital, this oversubscribed round will specifically fund the company's $5 million Microbiome Research Program and the growth of its Powered by Tiny B2B platform, which grew 4x last year. Tiny Health utilizes shotgun metagenomic sequencing to analyze gut and vaginal samples. Their research efforts include a 2025 study showing microbiome interventions can reduce infant eczema odds by 83%.

Timeline

  1. 2020: Tiny Health was founded.

  2. 2022: The company launched its testing platform.

  3. 2025: A published study showed an 83% reduction in infant eczema odds.

  4. September 29, 2026: Tiny Health announced the $33 million Series B round.

The Texas Context

The company's expansion addresses the growing prevalence of chronic illness, which currently affects 75% of U.S. adults and 45% of children. This move follows a broader industry shift in Austin toward using proprietary AI datasets to personalize preventative medicine.

Local healthcare providers may see increased access to microbiome research tools and educational resources provided by the firm. Customers can expect continued scaling of the company's B2B platform throughout the coming year.

The takeaway

Tiny Health's significant capital injection marks a major milestone for Austin's local biotech sector. Keep an eye on future clinical trial outcomes to see if their 2025 research findings regarding infant eczema are replicated on a larger scale.

Further reading

For more news on local life science companies, visit our Biotech section.

Live Poll

Is now a good time to invest in personalized microbiome or health testing for your household?